Expression of Tumor Stem Cell Marker CD133 in Non-small Cell Lung Carcinoma and Its Clinical Significance

[Objective] To investigate the expression of tumor stem cell marker CD133 in non-small cell lung carcinoma (NSCLC) and its relationship with NSCLC clinical significance. [Methods] Immunohistochemical staining was used to detect the expression of CD133 in 77 cases of patients with NSCLC. The relationship of the expression of CD133 with smoking index number, histological type, differentiation, lymphoid metastasis, T stage, N stage and survival time of the patients was analyzed. [Results] The death rate, live time (mid-live time), and three years survival rate of NSCLC patients after operation were 72.73%(56/77),1～84(s=19)month, 32.47% (25/77), respectively. Both mid-live time and survival rate of three years after operation in NSCLC patients were longer in negative lymphonode metastasis group than the positive ones(P 0.05). Out of 77 cases of NSCLC 40 cases (51.9%) showed positive expression of CD133. The expression of CD133 was associated positively with lymphoid metastasis (r=0.246, P 0.05), and inversely with survival time (P 0.05). In a COX multivariate analysis, the survival of NSCLC was significantly influenced by the histological type and expression of CD133. [Conclusion] The prognosis of NSCLC were associated with lymphoid metastasis and histological type. The expression of tumor stem cell marker CD133 was associated with lymphoid metastasis and prognosis in NSCLC.